Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ANVS401 (buntanetap) attacks neurodegeneration by inhibiting the formation of multiple neurotoxic proteins - amyloid beta, tau, alpha synuclein, and TDP43. It is being evaluated for the treatment of patients with mild to moderate Alzheimer’s disease.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
ANVS401 (buntanetap) works by inhibiting the formation of multiple neurotoxic proteins - amyloid beta, tau, alpha synuclein, and TDP43. It is being developed for mild to moderate Alzheimer’s disease.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
ANVS401 (Buntanetap) is a novel small molecule TINAPs Inhibitor which is currently being evaluated in phase 3 clinical trials of the treatment of Parkinson's Disease.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
ANVS401 (buntanetap) attacks neurodegeneration by inhibiting the formation of multiple neurotoxic proteins - amyloid beta, tau, alpha synuclein, and TDP43. It is being evaluated for the treatment of Parkinson's disease.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
ANVS402 (buntanetap) is an oral translational inhibitor of neurotoxic aggregating proteins, whose mode of action leads to a lower level of neurotoxic proteins and less toxicity in the brain. It is currently being investigated for Alzheimer’s and Parkinson's disease.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS402
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Annovis will fund the clinical development of Annovis’ lead drug candidate, ANVS402 a crystallized formulation of buntanetap, including the conduct of Annovis’ on-going and planned clinical trials.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS402
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Canaccord Genuity
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 31, 2023
Details:
ANVS401 (buntanetap) is an oral translational inhibitor of neurotoxic aggregating proteins, whose mode of action leads to a lower level of neurotoxic proteins and less toxicity in the brain. It is currently being investigated for Alzheimer’s and Parkinson's disease.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
ANVS401 (buntanetap) is an oral translational inhibitor of neurotoxic aggregating proteins, whose mode of action leads to a lower level of neurotoxic proteins and less toxicity in the brain. It is currently being investigated for Alzheimer’s and Parkinson's disease.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
ANVS401 (buntanetap) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which leads to a lower level of neurotoxic proteins and consequently less toxicity in the brain. It is currently being investigated for AD and PD.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
ANVS401 (buntanetap) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which leads to a lower level of neurotoxic proteins and consequently less toxicity in the brain. It is currently being investigated for AD and PD.
Lead Product(s): Buntanetap
Therapeutic Area: Neurology Product Name: ANVS401
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023